GLEEVEC IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的主要目的是评价格列卫的临床疗效。第二个目标是通过免疫组织化学方法评价PDGF受体的抑制作用；评价伊马替尼治疗前后的细胞因子谱；评价伊马替尼在HIV患者中的药代动力学；以及评价伊马替尼治疗的原发和继发性耐药的机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to evaluate the clinical response of Gleevec. The secondary objectives are to evaluate the inhibition of PDGF receptor as determined by immunohistochemistry; to evaluate cytokine profiles pre and post imatinib therapy; to evaluate the pharmacokinetic profile of imatinib in HIV patients; and to evaluate the mechanisms of primary and secondary resistance to imatinib therapy.